ArticleIranian journal of pathology2024
CD10 Expression in Colorectal Adenoma and Carcinoma and Its Association with the Pathological Prognostic Factors.
Article in Iranian journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Since early detection increases survival rates, colorectal carcinoma (CRC) is a major concern for researchers. CD10 is a cell membrane-bound metalloproteinase involved in carcinogenesis. Studies have associated it with the progression of CRC to advanced stages, metastasis, and venous invasions. We aimed to evaluate the immunohistochemical expression of CD10 in the tumor and stromal cells of colorectal adenoma and CRC and its correlation with the pathological prognostic factors. Methods: This cross-sectional study was conducted on radical resection specimens of CRC and polypectomy specimens of the colorectal adenomas received for routine histopathological evaluation in the Department of Pathology, Ramaiah Medical College and Hospitals, Bengaluru, from March 2021 to October 2022. Tumor morphology was examined by light microscopy, and CD10 expression was evaluated by immunohistochemistry. Descriptive statistics in terms of percentage and Chi-square test/ Fisher exact tests were used for the statistical analysis. Results: The study includes 46 cases of adenomas and CRCs each. Stromal CD10 expression was significantly higher in the carcinomas (63.4%) than in the adenomas (41.3%). Proliferative CRCs showed a significantly higher tumoral CD10 expression. The increase in the stromal CD10 expression in CRCs with increasing grades was found to be statistically significant. No significant association was seen between CD10 expression and other factors. Conclusion: The results indicate a potential role of CD10 in the adenoma-carcinoma sequence. The significant increase in proliferating and high-grade CRCs suggests that CD10 could prove to be a potential biomarker for aggressiveness and also a therapeutic target in CRCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.